Study of ARV-6723 alone or with pembrolizumab for advanced solid tumors
Treatments studied
Part of Brain & nervous system, Cancer, Digestive system, Ear, nose & throat, Genetic & congenital, Hormones & metabolism, Infections, Kidney & urinary, Lungs & breathing, Mouth & dental, Skin, Women’s health & pregnancy clinical trials.
This trial tests an experimental drug called ARV-6723, alone or with another drug called pembrolizumab, for people with advanced solid tumors that have not responded to other treatments. The goal is to see if these combinations can help shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced or metastatic solid tumor that cannot be removed with surgery.
- You must have already tried at least one type of immunotherapy (drugs like PD-1, PD-L1, CTLA-4, or LAG-3 inhibitors).
- You must have run out of standard treatment options, or your doctor thinks you cannot tolerate them, or you choose not to take them.
- Your cancer must have grown despite previous treatment, and you must have at least one measurable tumor that has not been previously treated with radiation (or has grown after radiation).
- You must be in generally good health, able to care for yourself (ECOG 0 or 1, or possibly 2 if your doctor discusses it).
- You must have adequate organ function, and no active brain metastases or certain heart conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two experimental drugs given together to treat advanced solid tumors that have not responded to previous treatments. The goal is to see if the combination helps shrink or control the cancer, and the study is for people who are otherwise in fairly good health.
This trial tests a new drug, ART6043, alone or with another drug called olaparib, for people with advanced or metastatic solid tumors. It may help if your cancer has specific DNA repair problems or if you have breast cancer with a BRCA gene mutation.
This trial tests a new drug called JZP898, given alone or with pembrolizumab, for adults with advanced solid tumors that have stopped responding to other treatments. It aims to see if this combination can help shrink tumors or slow their growth.
This trial tests a combination of two new treatments (QLP2117 and QL2107) for people with advanced solid tumors that have not responded to standard therapy. The goal is to see if the combination can shrink tumors or slow cancer growth.
This study tests a new drug called PLN-101095 in people with advanced solid tumors whose cancer has stopped responding to a common immunotherapy. The goal is to see if combining this new drug with pembrolizumab can help control the cancer again.
This trial tests a new drug called VIR-5525, either alone or combined with pembrolizumab (an immunotherapy), for people with advanced solid tumors that have not responded to other treatments or cannot undergo standard therapy. It focuses on certain cancer types and tumors with a specific genetic change (EGFR amplification).
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.